Abstract
For the past five years, NCI staff and collaborators have been pursuing the development and implementation of an unprecedented new investigational antitumor drug discovery screen. These efforts have not only been controversial, but have also been undertaken during an era of diminishing resources for antitumor drug screening and drug development at NCI. Moreover, numerous unanticipated obstacles, not only in the scientific and technical aspects, but also with respect to issues of management, organization, budget, personnel, laboratory facilities and space, have repeatedly threatened the viability of the project. There has also been immense pressure created by the reliance of many investigators worldwide for antitumor drug screening heretofore provided by NCI, and the fact that NCI has been essentially unable to provide any kind of routine screening support during most of the time the new screen has been under development. During 1986–87, the P-388 screen and other elements of the prior screening program were phased out entirely to free up necessary resources for research and development of the new screen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
National Cancer Institute planning to switch drug development emphasis from compound to human cancer-oriented strategy. Cancer Lett. 10(41):1–2, 1984.
Division of Cancer Treatment Board approves new screening program, natural products concepts. Cancer Lett. 11(9):4–5, 1985.
Division of Cancer Treatment gets okay to proceed with human cell line drug screening. Cancer Lett. 13(25): 1–2, 1987.
Reviewers report progress in new drug prescreen system development. Cancer Lett. 15(48): 1–5, 1989.
Workshop on “Disease-oriented Antitumor Drug Discovery and Development”, NIH, Bethesda, MD, January 9-10, 1985.
Ad Hoc review committee proceedings for National Cancer Institute In Vitro/In Vivo Disease-oriented Screening Project. NIH, Bethesda, MD, September 23–24, 1985.
Ad Hoc review committee proceedings for National Cancer Institute In Vitro/In Vivo Disease-oriented Screening Project. NIH, Bethesda, MD, December 8–9, 1986.
Ad Hoc review committee proceedings for National Cancer Institute In Vitro/In Vivo Disease-oriented Screening Project. NIH, Bethesda, MD, May 19–20, 1988.
Ad Hoc review committee proceedings for National Cancer Institute In Vitro/In Vivo Disease-oriented Screening Project. NIH, Bethesda, MD, November 13–15, 1989.
Kolberg RJ: Casting a wider net to catch cancer cures. J. NIH Research 2(April):82, 1990.
Boyd MR: National Cancer Institute drug discovery and development. In: Accomplishments in Oncology, E.J. Frei, E.J. Freireich (eds.), J.B. Lippincott Co., Philadelphia, pp. 68–76, 1986.
Jefford CW, Rinehart KL, Shield LS: Pharmaceuticals and the sea. Technomic Publishing AG, Lancaster, 1988.
Boyd MR, Shoemaker RH, McLemore TL et al: New drug development. In: Thoracic Oncology, J.A. Roth, J.C. Ruckdeschel, T.H. Weisenburger (eds.), W.B. Saunders Co., Philadelphia, pp. 711–721, 1989.
Boyd MR: Status of the NCI preclinical antitumor drug discovery screen. In: Cancer: Principles and Practice of Oncology Update, V.T. DeVita, S. Hellman, S.A. Rosenberg (eds), J.B. Lippincott, Vol. 3(10), Philadelphia, pp. 1–12, 1989.
Alley MC, Scudiero DA, Monks A et al: Feasibility of drug screening with panels of human tumor lines using a microculture tetrazolium assay. Cancer Res. 48:589–601, 1988.
Shoemaker RH, Monks A, Alley MC et al: Development of human tumor cell line panels for use in disease-oriented drug screening. In: Prediction of Response to Cancer Chemotherapy, T. Hall (ed), Alan Liss, New York, pp. 265–286, 1988.
Stinson SF, Alley MC, Kenney S et al: Morphologic characterization of human carcinoma cell lines. Proc. AACR 30:613, 1989.
Scudiero DA, Shoemaker RH, Pauli KD et al: Evaluation of a soluble tetrazolium/formazan assay for growth and drug sensitivity on culture. Cancer Res. 48:4827–4833, 1988.
Vistica DT, Skehan P, Scudiero DA et al: Tetrazolium-based assays for cellular viability: A critical examination of parameters which affect formazan production. AACR 30:612, 1989; Cancer Res., in press.
Vistica DT, Scudiero DA, Skehan P et al: Development and evaluation of a CO2-independent culture medium for use in a high-flux in vitro anticancer drug screen employing a broad panel of human tumor cell lines. JNCI in press.
Skehan P, Storeng R, Scudiero D et al: Evaluation of colorimetric protein and biomass stains for assaying in vitro drug effects upon human tumor cell lines. JNCI, in press.
Monks A, Scudiero D, Skehan P, Boyd M: Implementation of a pilot-scale, high flux anticancer drug screen utilizing disease-oriented panels of human tumor cell lines in culture. Proc. AACR 30:607, 1989; JNCI, in press.
Rubinstein LV, Pauli KD, Shoemaker RH et al: Correlation of screening data generated with a tetrazolium assay (MIT) versus a protein assay (SRB) against a broad panel of human tumor cell lines. JNCI, in press.
Pauli KD, Shoemaker RH, Hodes L et al: Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development mean graph and COMPARE algorithm. JNCI 81:1088–1092, 1989.
Pauli KD, Hodes L, Plowman J et al: Reproducibility and response patterns of IC50 values and relative cell line sensitivities from the NCI human tumor cell line drug screening project. Proc. AACR 29:488, 1988.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Boyd, M.R., Paull, K.D., Rubinstein, L.R. (1992). Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen. In: Valeriote, F.A., Corbett, T.H., Baker, L.H. (eds) Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Developments in Oncology, vol 68. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3492-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3492-1_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6548-8
Online ISBN: 978-1-4615-3492-1
eBook Packages: Springer Book Archive